Inceptionr LLC Acquires Shares of 2,610 IQVIA Holdings Inc. (NYSE:IQV)

Inceptionr LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,610 shares of the medical research company’s stock, valued at approximately $513,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at $236,120,000. First Business Financial Services Inc. increased its stake in shares of IQVIA by 2.6% in the fourth quarter. First Business Financial Services Inc. now owns 9,806 shares of the medical research company’s stock valued at $1,927,000 after buying an additional 253 shares in the last quarter. Aigen Investment Management LP acquired a new stake in shares of IQVIA in the fourth quarter valued at $1,547,000. Proficio Capital Partners LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $29,091,000. Finally, Assetmark Inc. increased its stake in shares of IQVIA by 21,537.3% in the fourth quarter. Assetmark Inc. now owns 49,333 shares of the medical research company’s stock valued at $9,694,000 after buying an additional 49,105 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 3.4 %

NYSE:IQV opened at $191.69 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.72. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $33.80 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business’s 50-day simple moving average is $197.79 and its 200-day simple moving average is $212.87.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on IQV. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Leerink Partners reiterated an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.